Drug General Information (ID: DDIWM75NDX)
Drug Name			Etodolac		Drug Info		Tirofiban		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Analgesics				Fibrinolytic Agents
Structure

Mechanism of Etodolac-Tirofiban Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Etodolac				Tirofiban
Mechanism		Risk of bleeding Antiplatelet effects				Risk of bleeding Antiplatelet
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Etodolac and Tirofiban

Recommended Action
Management		It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.

References
1	Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
2	Product Information. ReoPro (abciximab). Lilly, Eli and Company, Indianapolis, IN.